Compare · AKER vs IDXX
AKER vs IDXX
Side-by-side comparison of Akers Biosciences Inc. (AKER) and IDEXX Laboratories Inc. (IDXX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AKER and IDXX operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- IDXX carries a market cap of $45.00B.
- IDXX has hit the wire 2 times in the past 4 weeks while AKER has been quiet.
- IDXX has more recent analyst coverage (23 ratings vs 0 for AKER).
- Company
- Akers Biosciences Inc.
- IDEXX Laboratories Inc.
- Price
- -
- $565.97+0.89%
- Market cap
- -
- $45.00B
- 1M return
- -
- -1.66%
- 1Y return
- -
- +30.49%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- 1991
- News (4w)
- 0
- 2
- Recent ratings
- 0
- 23
IDEXX Laboratories Inc.
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Latest AKER
- SEC Form S-3/A filed by Akers Biosciences Inc. (Amendment)
- SEC Form 3: Williams Caroline C claimed ownership of 5,017,423 units of Common Stock
- SEC Form 4 filed by EAGLE CRAIG
- SEC Form 3 filed by EAGLE CRAIG
- Akers Biosciences Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Changes in Control of Registrant, Material Modification to Rights of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 4 filed by Kaplin Adam
- SEC Form 3 filed by Kaplin Adam
- SEC Form 4: Schreiber Christopher C exercised 131,750 units of Common Stock at a strike of $0.00 and disposed of $227,798 worth of Common Stock (46,113 units at $4.94), increasing direct ownership by 3,292% to 88,238 units to cover withholding tax
- SEC Form 4 filed by Uzonwanne Jude
- SEC Form 4: Chapman Christopher C JR was granted 96,475 units of Common Stock
Latest IDXX
- Citigroup initiated coverage on IDEXX Labs with a new price target
- IDEXX Laboratories to Release 2026 First Quarter Financial Results
- IDEXX Announces UK Availability of Cancer Dx Panel for Early Detection of Canine Lymphoma
- SEC Form DEFA14A filed by IDEXX Laboratories Inc.
- SEC Form DEF 14A filed by IDEXX Laboratories Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by IDEXX Laboratories Inc.
- IDEXX Laboratories Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- SEC Form PRE 14A filed by IDEXX Laboratories Inc.
- EVP, GC & Corporate Secretary Underberg Sharon E. exercised 197 shares at a strike of $505.53, increasing direct ownership by 3% to 7,138 units (SEC Form 4)
- Executive Vice President Hunt Nimrata sold $1,115,577 worth of shares (1,758 units at $634.57), decreasing direct ownership by 9% to 18,141 units (SEC Form 4)